Kelun-Biotech Partners with Windward Bio for Phase 2 Asthma Trial of SKB378/WIN378 Kelun-Biotech announces the initiation of a Phase 2 clinical trial for SKB378/WIN378, a novel treatment for asthma in partnership with Windward Bio.

Kelun-Biotech Partners with Windward Bio for Phase 2 Asthma Trial of SKB378/WIN378 #China #Chengdu #Kelun-Biotech #Windward_Bio #SKB378

Kelun-Biotech and Windward Bio Forge Strategic Collaboration for TSLP Monoclonal Antibody Development Sichuan Kelun-Biotech Biopharmaceutical Co. has partnered with Windward Bio to develop SKB378/HBM9378, a promising monoclonal antibody targeting severe respiratory diseases.

Kelun-Biotech and Windward Bio Forge Strategic Collaboration for TSLP Monoclonal Antibody Development #China #Chengdu #Kelun-Biotech #Windward_Bio #TSLP_Antibody

Novo Holdings Fuels Windward Bio's $200 Million Launch for Asthma Treatments Novo Holdings has invested in a $200M Series A financing for Windward Bio, aiming to develop innovative treatments for asthma and COPD with a focus on long-acting therapies.

Novo Holdings Fuels Windward Bio's $200 Million Launch for Asthma Treatments #Novo_Holdings #Denmark #Copenhagen #Windward_Bio #WIN378

Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment Harbour BioMed and Windward Bio enter a license agreement for HBM9378, an innovative antibody aimed at treating immunological diseases, signaling promising medical advancements.

Harbour BioMed Partners with Windward Bio to Advance HBM9378/SKB378 for Immunological Disease Treatment #None #HBM9378 #Windward_Bio #Harbour_BioMed